SHERIDAN, WYOMING – April 14, 2026 – NS Pharma, a US-based biopharmaceutical company and subsidiary of Japan's Nippon Shinyaku Co., Ltd., has presented 4.5 years of clinical trial data for its Duchenne muscular dystrophy candidate Brogidirsen — the latest in a series of advances from a pipeline targeting multiple rare diseases. The data was shared at the 2026 MDA Clinical & Scientific Conference in early March, building on results first presented at a major international neuromuscular conference in late 2025. A second DMD compound separately earned FDA Orphan Drug Designation in September 2025, and NS Pharma is simultaneously running a global Phase 2 trial for NS-229, its candidate for a rare inflammatory disease called EGPA. Taken together, these developments mark a significant stretch of progress for a company whose research touches some of the most underserved patient communities in medicine.
Brogidirsen's Long-Term Clinical Results
Brogidirsen (NS-089/NCNP-02) is NS Pharma's lead candidate for Duchenne muscular dystrophy, developed using exon-skipping technology. The dystrophin gene — which is essential for muscle function — contains 79 exons, and mutations in specific exons cause DMD by preventing the body from producing a working version of the dystrophin protein. Exon-skipping therapies are designed to route around those mutations, allowing the body to produce a shorter but still functional form of dystrophin that can slow disease progression. On March 6, 2026, NS Pharma presented 4.5-year clinical trial data for Brogidirsen at the MDA Clinical & Scientific Conference, following 3.5-year results shared at the World Muscle Society Congress in October 2025. The growing dataset gives researchers and physicians a more sustained view of how the therapy performs as patients continue through long-term treatment.
Second DMD Candidate Earns FDA Orphan Drug Status
NS Pharma's Duchenne program does not rest on Brogidirsen alone. A second candidate, NS-051/NCNP-04, received FDA Orphan Drug Designation in September 2025 — a regulatory milestone that formally recognizes a treatment as targeting a rare and serious condition with insufficient existing options. This designation comes with practical benefits for the developer, including tax credits for clinical trial expenses and a period of market exclusivity if the drug eventually earns full approval. More significantly for patients, it signals that the FDA has acknowledged the unmet medical need NS-051/NCNP-04 is intended to address and is committed to supporting its development path. Having two active DMD candidates advancing at different stages meaningfully strengthens NS Pharma's overall position in the Duchenne space.
A New Program for a Rare Inflammatory Disease
Alongside its DMD work, NS Pharma is developing a treatment for eosinophilic granulomatosis with polyangiitis — EGPA — a rare autoimmune condition driven by an overactive immune response that causes asthma, skin rashes, and nerve pain. NS Pharma's candidate, NS-229, is a selective JAK1 inhibitor designed to block a specific immune signaling pathway that contributes to EGPA's damaging inflammation without broadly suppressing the immune system. NS-229 is currently enrolling in a global Phase 2 clinical trial, placing NS Pharma among the limited number of companies actively pursuing new therapeutic options for this condition. The international scope of the trial reflects an intent to gather evidence across a diverse patient population.
Why it matters
Rare diseases affect relatively small numbers of people, but for those living with conditions like Duchenne or EGPA, treatment options are often painfully limited and the consequences of disease progression are severe. Duchenne is a progressive muscle-wasting disease that typically emerges in early childhood, and while some treatments exist, new options targeting different genetic mutations remain urgently needed. The 4.5-year Brogidirsen dataset is among the longer sets of follow-up data available for an exon-skipping DMD therapy, offering a more meaningful window into long-term outcomes than earlier readouts could provide. The Orphan Drug Designation for NS-051/NCNP-04 widens the DMD pipeline with a second active candidate, and the Phase 2 EGPA trial extends NS Pharma's reach into rare inflammatory disease. For patients, caregivers, and rare disease advocates, this kind of steady, multi-front pipeline progress represents the kind of movement the community needs to see.